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A recent advance that has revitalized toxi-
cology studies in the past couple of decades 
is Frontiers in Genetics “toxicogenomics,” 
the  study  of  the  effects  of  environmen-
tal toxins on global changes within a cell 
or tissue as related to genomic variables. 
“Transcriptional  toxicogenomics”  is  the 
study of global gene expression patterns 
after  administering  a  toxin.  Similarly, 
“toxicoproteomics” is the study of global 
changes  in  protein  levels  or  post-trans-
lational  modifications;  while  “toxicome-
tabolomics” is the study of global changes 
in metabolite levels after administering a 
toxin. A new field called “toxicoepigenom-
ics”  or  more  simply,  the “epigenetics  of 
toxicology,” is the study of global epigenetic 
changes in a cell that are caused by exposure 
of a cell, tissue, or organism to a toxin or 
drug. Frontiers in Toxicogenomics provides a 
format for presenting cutting-edge reviews 
and studies in the frontiers of all branches 
of toxicogenomics.
One type of study within the area of 
transcriptional  toxicogenomics  called 
“genetical genomics” or “genetics of gene 
expression,” is the combination of quan-
titative  trait-locus  (QTL)  and  whole-
genome expression analyses (Brem et al., 
2002; Broman, 2005). In genetical genom-
ics, the investigator treats the expression of 
each of the ∼20,000 genes in an organism 
as a quantitative trait and identifies cis-
expression QTL (eQTL) in cis-regulatory 
sequences and trans-eQTL in trans-acting 
factors that regulate expression of co-regu-
lated genes in specific pathways. Genetical 
toxicogenomics adds a new dimension to 
genetical genomics by studying the effects 
of an environmental toxin on global gene 
expression patterns (Ruden et al., 2009). 
Such studies are theoretically very power-
ful because they not only tell which genes 
are induced in a particular tissue (such as 
a brain region) by the toxin, but they also 
allow  the  identification  of  trans-acting 
factors and cis-acting sequences that are 
regulated  by  the  toxin.  Toxicogenetical 
genomic studies in mice have the advan-
tage that thousands of recombinant inbred 
lines  have  recently  been  generated  in  a 
collaborative cross amongst eight differ-
ent wild type strains of mice (Churchill 
et al., 2004). Rats are sometimes preferred 
models for toxicological screens because 
they have much larger organs than mice, 
allowing  for  easier  gene  and  protein 
expression analyses because much more 
material can be obtained compared with 
mice. Recombinant inbred lines have also 
been developed in rats, and some labora-
tories have conducted genetical genomics 
and genetical toxicogenomics analyses in 
rats, especially in the rat brain.
The transcriptional toxicogenomic stud-
ies have mostly been done with recombinant 
inbred lines, such as in mice, C. elegans, 
and Drosophila, and utilized gene expres-
sion microarrays. However, next-generation 
sequencing technologies allow new types of 
transcriptional  toxicogenomic  studies  to 
be conducted. For example, “speed QTL” 
analyses can be done by selecting a large 
population of model organisms for a par-
ticular trait, such as lifespan after feeding 
a toxin, for several generations and then 
sequencing the genome of the long-living 
descendents (Lai et al., 2007). The single 
nucleotide polymorphisms (SNPs) that are 
enriched in the long-living descendents are 
located in candidate toxin-survival genes 
which can be studied in follow up genetic 
and biochemical studies. Third generation 
sequencing  technologies  will  soon  make 
the “$1000 genome” a reality and will not 
only allow “personalized medicine,” which 
is  using  a  person’s  genome  sequence  to 
optimize a drug regimen to treat a   disease 
(Ruden,  2007),  but  also  “personalized 
  toxicogenomics” which uses this genome 
information to determine a person’s sus-
ceptibility to an environmental toxin.
Toxicoproteomics  and  toxicometabo-
limics  are  new  areas  that  utilize  state-
of-the-art mass spectrometry and other 
sensitive assay systems that can quantify 
protein, peptide, and metabolic levels in 
a population of model organisms. Instead 
of gene expression being the quantitative 
trait, as in transcriptional toxicogenom-
ics, protein, and metabolite levels can be 
used as quantitative traits. In this manner, 
protein QTL (pQTL) and metabolite-QTL 
(mQTL)  can  be  identified  in  both  cis- 
and  trans-genes  that  regulate  the  levels 
of molecules.
Toxicoepigenomics is the study of global 
epigenomic changes, such as DNA meth-
ylation  changes,  histone  modifications, 
or microRNA changes, that are caused by 
exposure  to  toxins.  In  this  manner,  epi-
genetic-QTL  (epiQTL)  can  be  identified 
that identify cis- and trans-regulatory ele-
ments and factors that alter the epigenome 
in  response  to  a  toxin.  It  is  known  for 
instance that prenatal lead exposure causes 
hypomethylation of repeats in humans. It 
would be interesting to study global meth-
ylation patterns after exposure to lead and 
other toxins in large populations.
In  conclusion,  toxicogenomics  is  an 
exciting new field that has revitalized toxi-
cology research. No longer need toxicolo-
gists study only LD50 values (lethal dose 
that kills 50% of the population) and use 
death alone as a toxicology endpoint. Now 
toxicologists can perform studies with much 
more subtle endpoints, such as gene expres-
sion, protein or metabolite levels, and epig-
enomic changes. Frontiers in Toxicogenomics 
provides a format for present research and 
reviews in this exciting new field.Frontiers in Genetics  | Toxicogenomics    March 2011  | Volume 2  | Article 12  |  2
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